Funding to Fuel Product Development, Expand Market Reach, and Accelerate Revenium’s Mission to Bring Full-Stack Economic Intelligence to the AI Ecosystem

HERNDON, Va., Nov. 20, 2025 — Revenium, a financial intelligence platform for managing and optimizing AI spend, today announced the closing of $13.5 million in Seed round funding led by Two Bear Capital with participation from WestWave Capital. By transforming AI from an opaque cost center into a scalable, governable engine for growth, Revenium provides valuable solutions that are essential across all businesses and industries. This investment will fuel the company’s product development, expand its market reach, and accelerate Revenium’s mission to bring full-stack economic intelligence to the AI ecosystem. Concurrently with the funding announcement, Revenium debuted a new website and digital resources designed to drive product discovery and customer adoption.

As organizations scale AI across products and operations, visibility into cost, performance, and ROI has become critical. Revenium delivers a comprehensive platform that connects AI activity to business outcomes, providing economic visibility across models, agents, and workflows. The platform delivers real-time event-level telemetry, anomaly detection, and budget guardrails that help teams cut AI costs and prove ROI. Revenium’s core offering focuses on converting usage events into auditable invoices or internal charge-backs, providing companies with a way to manage escalating AI costs. Furthermore, Revenium’s approach emphasizes fast developer ergonomics and low-friction installations, allowing organizations to “start in minutes, not months.”

“We see this moment as the convergence of two forces: the rise of agentic AI and the need for economic accountability. Revenium ensures companies can scale with visibility, control, and confidence,” said John Rowell, co-Founder and CEO of Revenium. “We are grateful for the support of investors like Two Bear Capital and WestWave Capital, who understand our mission, believe in the products we are delivering, and see the opportunity in front of us. This funding, coupled with the new digital presence we debuted, marks a new phase of development as Revenium establishes itself as the system of record for AI economics.”

“Revenium enters the market amid rapid adoption of multi-agent and autonomous AI workflows, a shift that multiplies both capability and cost. As AI moves from experimental projects to business-critical systems, organizations need a system of record for AI economics to prevent runaway spend and convert AI investments into predictable growth,” said Mike Goguen, Founder and Managing Partner of Two Bear Capital. “Revenium is positioned to lead the market by providing the financial solutions this moment demands. Two Bear Capital is thrilled to be partnering with John Rowell and the entire team at Revenium to build this incredible company.”

“As one of the first seed investors in Revenium, WestWave Capital is excited to support Revenium as they build the next wave of innovation in AI economics and usage-based billing space,” said Gaurav Manglik, General Partner of WestWave Capital. “We were drawn to this team’s deep product insight and strong execution, and we look forward to supporting their next phase of growth and product development.”

With new funding and a strengthened digital presence, Revenium is expanding its go-to-market strategy to meet rising demand from enterprises and AI-native startups. The company is hiring across engineering, product management, and customer success to accelerate delivery and adoption of its platform. Revenium’s product roadmap focuses on enabling real-time spend attribution, consolidation across model providers, and operational guardrails that scale with enterprise requirements.

About Revenium
Revenium is the world’s first AI economics system of record, delivering real-time visibility into the cost, performance, and ROI of AI operations. By connecting every model, agent, and transaction to its true economic footprint, Revenium empowers organizations to optimize margins, manage risk, and scale AI responsibly. Built for the era of intelligent automation, Revenium provides the financial layer that ensures AI innovation drives measurable, sustainable business value. For more information, visit: www.revenium.ai.

About Two Bear Capital
Founded in 2019 by Mike Goguen, Two Bear Capital is a venture capital firm investing in brilliant entrepreneurs with breakthrough solutions to complex and critical problems. With its unique approach to venture capital, Two Bear Capital’s vision is to build enduring, high-impact businesses that benefit society while delivering for investors. The firm primarily focuses on early founder-led companies with disruptive life sciences and technology innovations. Two Bear Capital has offices in Menlo Park, San Diego, Boston, and New York, with its home base in Whitefish, Montana. For more information, visit:www.twobearcapital.com.

About WestWave Capital
WestWave Capital is an early-stage venture firm investing in deep-tech, AI-native, enterprise software companies. For more information, visit: www.westwavecapital.com. 

Media Contact
Mckenzie Rowell
Communications Lead, Revenium
[email protected]

SOURCE Revenium

New partnership will enable Antheia to increase scale and accelerate time to market for future product launches

MENLO PARK, Calif. and PARSIPPANY, N.J., Nov. 20, 2025 — Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and TAPI – Technology and API Services, today announced a strategic partnership. Antheia will leverage TAPI’s next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialize its pipeline of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs). 

This partnership unites Antheia’s innovative biosynthesis platform with TAPI’s advanced bioprocessing and manufacturing capabilities, enabling efficient, reliable, and high-quality production of critical pharmaceutical ingredients at commercial scale. The existing infrastructure, capacity, and quality management systems TAPI provides are particularly well suited for Antheia’s processes, enabling continuous growth and long-term support for multiple products in the company’s pipeline.

“As demand for Antheia’s products continues to grow, our ability to both increase the scale of existing products and accelerate future product launches is critical,” said Zack McGahey, COO of Antheia. “With nearly a century of API manufacturing experience, TAPI brings a depth of expertise, as well as state-of-the-art infrastructure that will empower us to meet growing customer demand and deliver on our commercialization strategy. Welcoming TAPI as a manufacturing partner will play a significant role in our efforts to transform pharmaceutical supply chains, end drug shortages, and propel innovation in this space.”

Advanced biosynthesis is the transformative technology of the 21st century for pharmaceutical manufacturing. With Antheia’s platform and vast pipeline of products that are essential to public health, and TAPI’s long-standing legacy of scaling complex processes and driving pharmaceutical progress, this partnership is poised to strengthen these vital global supply chains.

“Our collaboration with Antheia reflects the essence of what we strive for at TAPI – Advancing Health from the Core and bringing together scientific innovation and manufacturing excellence to accelerate our partners’ success,” said R Ananth, CEO of TAPI. “Through our flexible tech transfer model and collaborative, problem-solving approach, we’re able to adapt seamlessly to our partners’ needs and scale their innovations with confidence. Leveraging our Center of Excellence for Biocatalysis and Enzyme Development, we’re particularly excited to support Antheia’s biosynthetic platform with the advanced fermentation and enzymatic capabilities that make these complex processes both efficient and commercially viable.”

Today’s news comes on the heels of Antheia’s $56 million Series C fundraise and the company’s successful commercialization of thebaine in 2024.

About Antheia:
Antheia is the next-generation pharmaceutical ingredient producer with a mission to end drug shortages. Using advanced biosynthesis and fermentation technology, Antheia’s biomanufacturing platform enables rapid, efficient, agile, and on-demand production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) that are critical to public health. This highly flexible approach supports the needs of a growing society and improves global access to essential medicines. Founded in 2015, Antheia has grown into a commercial stage company with its first product to market, an active customer pipeline, and near-term product launches. For more information on how Antheia is transforming pharmaceutical supply chains, visit www.antheia.bio.

About TAPI:
TAPI is a global leader in the development and manufacturing of active pharmaceutical ingredients (APIs), building blocks and key starting materials (KSM’s) providing one of the industry’s most comprehensive API portfolios. TAPI also offers customized CDMO services, utilizing their extensive expertise in a wide range of technologies to meet the diverse needs of partners, ensuring flexibility and excellence in every project. With 4,100 employees, a global footprint in 100+ countries, 13 sites worldwide, and a robust portfolio of 350+ high-quality products, TAPI’s operations are integral to the delivery of high-quality, safe and effective medications to patients worldwide, supported by a sophisticated supply chain, focused innovative manufacturing, regulatory and quality excellence and a commitment to sustainability. For more information about how TAPI is advancing health from the core, visit www.tapi.com.

MEDIA CONTACTS:

Antheia:
Mission North for Antheia
[email protected]

TAPI:
[email protected]

SOURCE Antheia

SAN DIEGO, Nov. 20, 2025 — Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen’s lead program, ANPD001, for moderate to advanced Parkinson’s disease.

The Series C round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners, with participation from existing investors including Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, and LifeForce Capital, among others. New investors include Kite, a Gilead Company  (Nasdaq:GILD), Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures, and others. This latest funding brings Aspen’s total capital raised to date to over $340 million, including an $8 million grant from California Institute for Regenerative Medicine (CIRM).

In conjunction with the financing, Cindy Perettie, Executive Vice President and Global Head of Kite, a Gilead Company, will join Aspen’s board of directors.

“This financing marks a pivotal moment for Aspen as we accelerate our mission to deliver personalized regenerative therapies for people with Parkinson’s disease and beyond,” said Damien McDevitt, Ph.D, President and Chief Executive Officer of Aspen Neuroscience. “We are grateful for the confidence our investors have shown in our science, team, vision, and market opportunity. The significant experience and deep capital resources our investor syndicate brings will be instrumental in advancing Aspen’s next phases of clinical development and commercial readiness. Their strategic guidance and financial support empower us to scale our operations, expand our pipeline, and bring transformative therapies closer to those in need.”

Advancing Clinical Innovation and Commercial Readiness

The Series C financing will be used to:

• Support ongoing clinical trials of ANPD001, Aspen’s lead autologous cell therapy candidate for Parkinson’s disease.
• Scale manufacturing capabilities to meet clinical and future commercial demand.
• Advance Aspen’s pipeline of autologous iPSC-derived therapies for additional neurological indications.

Aspen’s proprietary manufacturing platform leverages machine learning and advanced genomics to produce the highest quality personalized cells for each patient, setting a new benchmark for consistency and scalability in cell therapy.

This financing follows initiation of dosing for the Phase 1/2a Cohort 3 commercial formulation and presentation of promising safety and efficacy data at six months post-procedure for Cohort 1.

“It is significant to see a private financing of this quality. Securing this round is a testament to how this team is rising above with innovation in product characterization, manufacturing automation, and positive clinical results,” said Faheem Hasnain, Board Chairman of Aspen Neuroscience. “Aspen is poised to deliver the first potentially disease-modifying therapy for the millions of patients waiting for these advancements.”

About ANPD001
ANPD001 is the most advanced autologous investigational cell therapy in the United States for treating Parkinson’s disease. More information about the Phase 1/2a trial is available at clinicaltrials.gov (NCT06344026).

Aspen’s personalized approach means that patients do not require immunosuppressive (IS) drugs to dampen the body’s immune response against foreign cells. This approach is intended to avoid IS‑associated adverse events, eliminate IS drug‑monitoring requirements, and enable dosing for those with contraindications to IS therapies.

ANPD001 has received Fast Track designation by the U.S. Food & Drug Administration (FDA).

Recent progress on Cohort 3: Aspen has initiated Cohort 3 in the ASPIRO Phase 1/2a trial, marking the first administration of the commercial formulation of ANPD001, which was deemed preclinically comparable to the formulation used in the first two cohorts. Earlier cohort six‑month data reported at IAPRD demonstrated strong safety and tolerability with clinician‑ and patient‑reported improvements, achieved without immunosuppression. The cryopreserved, ready‑to‑dose formulation is designed to streamline surgical workflows and reduce demands on hospital cell processing labs.

Three pillars that differentiate ANPD001 and Aspen’s platform:

• Manufacturing Platform: A proprietary, high‑tech process converts a small biopsy of the patient’s own skin cells into induced pluripotent stem cells (iPSCs) and then into dopaminergic neuronal precursor cells (DANPCs), with machine‑learning–based genomics tests assessing quality at each stage to deliver high‑quality personalized cells.
• Therapeutic Platform: Autologous iPSC‑derived DANPC therapy that uses each patient’s own cells, designed to avoid immune rejection and eliminate the need for long‑term immunosuppression, while preserving the personalized nature of treatment.
• Proprietary Device for Cell Transplantation: A precision delivery system that combines a metered‑dosing syringe with MRI guidance for sub‑millimeter accuracy, enabling minimally invasive surgery and a streamlined clinical workflow.

About Aspen Neuroscience
Headquartered in San Diego, Aspen Neuroscience, Inc. is a clinical-stage private biotechnology company focused on autologous regenerative medicine. Aspen’s patient-derived iPSC platform enables the development of personalized therapies for diseases with high unmet medical needs. The company’s pipeline includes ANPD001 and additional programs targeting neurodegenerative disorders.

For more information, visit www.aspenneuroscience.com.

SOURCE Aspen Neuroscience, Inc.

With over $1.5B in bookings annually, Peek is poised to become the ‘Shopify for Experiences’

SAN FRANCISCO, Nov. 20, 2025 — Peek, the operating system for experiences, today announced the acquisitions of ACME Ticketing and Connect&GO, cementing its position as the market leader powering the $330B experiences industry. The company also raised $70M in funding led by growth equity firm Springcoast Partners. Existing investors include WestCap, Goldman Sachs Alternatives, Eric Schmidt and Kayak founder Paul English.

With the acquisitions of ACME and Connect&GO, Peek expands its reach to over 150 million consumers across museums, theme parks, tours and activities, and cultural attractions—the full spectrum of how people spend their leisure time. ACME brings deep expertise in ticketing infrastructure, memberships, and donations for iconic cultural institutions. Connect&GO adds powerful all-in-one attraction management, including RFID technology and on-site visitor tools for complex venues. Peek customers include the industry’s largest and most sophisticated attractions, such as MoMA, Whitney Museum, Seattle Aquarium, Bryant Park, Looping Group & Museum of Ice Cream.

“Peek has demonstrated a masterclass in innovation and scale within the industry,” says Dominic Gagnon, CEO of Connect&GO. “We’re thrilled to join forces with Peek given our shared mission, and we will rapidly work to combine our knowledge and resources to deliver even stronger solutions for the attractions we serve.”

The acquisitions also drew strong support from Peek’s new and existing investors. “Peek offers the comprehensive tech stack this industry needs to keep pace with shifting consumer and workforce behavior,” said Waqar Islam of Springcoast, who led the Series D funding. “With 40% of operators not utilizing online booking tools, we’re still in the very early innings of empowering operators to thrive in a digital-first world. Peek’s deep investment in core tech infrastructure, AI, and payments uniquely positions them to unlock the industry’s full potential and serve as the operating system for experiences.”

A New AI Era for Tech & Experiences

Peek’s early investment in AI comes as the activities industry stands at a digitization inflection point. The company won Arival’s 2024 Industry Innovation Award for Peek Copilot, its integrated AI platform, which has already delivered 5-20% revenue growth for operators through its Dynamic Pricing feature alone.

“Peek has built the best product in the experiences space,” said Bill Shaughnessy, CEO of ACME. “Their end-to-end tooling helps merchants across every operational need, and their AI dramatically streamlines operations, from dynamic pricing to conversion optimization and beyond. Combining this with ACME’s unparalleled ability to turn visitors into loyal members and donors, we’re going to have a huge impact on the cultural institutions we serve.”

The company also leverages AI agents to solve key industry challenges such as fraud detection and data analysis. “We have hundreds of AI agents working behind the scenes to save merchants thousands of hours on repetitive tasks,” said Ruzwana Bashir, CEO of Peek. “We’ve built an AI-powered system that works 24/7, transforming how operators understand their customers and optimize their operations across every touchpoint.”

“We’re seeing more of our audience planning their outings through AI tools, video platforms, and influencers, especially across TikTok and Instagram,” said Xiaoyi Chen, CEO of LuminoCity. “For merchants, this shift creates a real opportunity to build and own our direct demand rather than relying solely on third-party channels. Peek is the only partner we’ve seen that’s proactively building the technology to support this future.”

“Our mission at Peek has always been about empowering our customers to deliver extraordinary experiences. These acquisitions and new funding enable us to further accelerate our product innovation and deepen our support, ultimately helping operators grow their businesses,” added Bashir. “We’re committed to giving activities operators the tools they need to not just compete, but to lead, in today’s rapidly evolving experiences economy.”

About Peek
Peek is the operating system powering the experiences industry—from museums and attractions to tours and activities. With over $7B in bookings, Peek’s AI-powered platform has helped thousands of merchants to increase revenues, save time and deliver seamless guest experiences. Customers include MoMA, Whitney Museum, Seattle Aquarium, Bryant Park, Looping Group & Museum of Ice Cream. The company has raised over $150 million from institutional investors including Springcoast Partners, WestCap and Goldman Sachs Alternatives. Learn more at www.peek.com.

About Springcoast Partners
Established in 2023, Springcoast is a New York-based growth equity firm focused on partnering with market-leading software and technology companies. To learn more about Springcoast, please visit www.springcoast.com.

Media Contact
[email protected]

SOURCE Peek

LUGANO, Switzerland, Nov. 20, 2025 — Exponential Science (ES) announced today the launch of the ES Accelerator, a founder-focused programme powered by venture builder H-FARM — ranked among the Financial Times’ Top 10 European Startup Hubs — and designed to support ambitious early-stage companies leveraging exponential technologies, including distributed ledger technology (DLT), artificial intelligence, and quantum computing, to build an equitable and open future.

The accelerator provides selected startups with an equity investment, mentorship from industry experts, and access to Exponential Science’s extensive ecosystem of partners, academic institutions, and initiatives. This includes the MiCA Crypto Alliance, Nodiens, as well as Hedera and its wider ecosystem.

‘The most transformative companies emerge at the intersection of breakthrough technology and urgent global needs,’ said Nikhil Vadgama, Director at Exponential Science. ‘The ES Accelerator is designed to identify and support those rare teams with the vision, expertise, and determination to build the infrastructure for the next phase of human progress.’

The programme targets pre-seed and seed-stage companies led by teams of two or more founders with deep technical or domain expertise. Ideal candidates have demonstrated a working prototype or MVP, a clear global vision for solving significant problems, and preferably have or are developing proprietary intellectual property that strengthens long-term defensibility.

Programme Highlights:

Structured Support: The ES Accelerator offers intensive workshops covering business model design, product development, go-to-market strategy, and fundraising preparation, alongside dedicated one-to-one mentorship from experts across blockchain, hashgraph technology, AI, governance, and emerging technologies.

Cohort-Based Learning: Participating startups progress alongside a curated group of peers, fostering collaboration and shared growth throughout the programme.

Ecosystem Access: Portfolio companies gain connections to Exponential Science Foundation’s network of ecosystem partners, academic institutions, and strategic initiatives, accelerating their path to market.

Founder-Friendly Investment: All accepted startups receive an equity investment, with the potential for follow-on investment upon programme completion. Detailed investment terms are provided to applicants following application submission.

The ES Accelerator reflects Exponential Science’s commitment to backing founders building real solutions to global challenges through exponential technologies, supporting the infrastructure, governance, and applications that will define the next generation of innovation.

About Exponential Science

Exponential Science is a foundation focused on supporting breakthrough technologies that accelerate human progress. Through strategic investments and ecosystem initiatives, Exponential Science backs founders building at the frontier of DLT, AI, and deep-tech to create more equitable, transparent, and open systems for the future.

For more information about the ES Accelerator or to apply, visit:
www.exp.science/es-accelerator.

Media Contact:
[email protected]

About H-Farm

Founded in 2005, H-FARM is a venture builder and innovation ecosystem spanning education, startups, healthcare, digital consultancy, sports, and applied research. Named Italy’s Top Startup Hub by the Financial Times, it has supported over 150 startups, achieving 50+ exits and two unicorns (Depop and Soldo).
https://www.h-farm.com/ 

New capital and compute infrastructure will accelerate Luma AI’s path towards Multimodal AGI – AI that can simulate reality and help humans in the physical world.

HUMAIN to build Project Halo, one of the world’s largest AI compute clusters that will include the training of World Models, the next step in AI after LLMs – a potential trillion-dollar opportunity spanning entertainment, marketing/brands, education, world understanding, and robotics industries.

Partnership includes HUMAIN Create, an initiative to build AI models trained on Arabic and regional data, helping enterprises and governments across MENA adopt culturally aligned AI.

PALO ALTO, Calif. and WASHINGTON, Nov. 19, 2025 — Luma AI, the frontier artificial intelligence company building multimodal AGI, today announced it has raised $900 million in Series C funding, led by HUMAIN, a PIF company delivering global full-stack AI solutions, with significant participation from AMD Ventures, and existing investors Andreessen Horowitz, Amplify Partners, and Matrix Partners.

 This Series C is a milestone in the company’s mission to build multimodal general intelligence: AI that can generate, understand, and operate in the physical world. To train and deploy these next-generation AI systems, Luma AI will become a customer of HUMAIN as HUMAIN builds Project Halo, a 2-gigawatt AI supercluster in Saudi Arabia, making it one of the world’s largest compute infrastructure buildouts. 

 Announced today in Washington, D.C., at the U.S.- Saudi Investment Forum on the visit of the Crown Prince HRH Mohammad bin Salman Al-Saud, the companies unveiled a joint roadmap to advance the frontier of multimodal intelligence. This new funding and infrastructure will accelerate Luma AI’s efforts to train large-scale World Models, foundational AI that goes beyond LLMs and learns from humanity’s digital footprint in video, audio, and language, to build products in HUMAIN Create that understand and simulate reality for robotics, entertainment, advertising, gaming, and personalized education at a global scale.

“HUMAIN is the perfect partner for this next stage in Luma AI’s explosive trajectory,” said Amit Jain, CEO and co-founder of Luma AI. “To create AI that can help humanity in the physical world and expand our understanding of the universe, we need to build systems that can learn from a quadrillion tokens of information – roughly the collective digital memory of humanity – contained in video, image, audio, and language. HUMAIN is deploying frontier compute infrastructure at impressive speed, and this is critical to achieving Luma AI’s mission. We are also partnering deeply across customized models, go-to-market, and deployment of frontier capabilities to build a full end-to-end value-chain for multimodal AI.”

“This investment underscores an important point in HUMAIN’s philosophy: we are not only funding the next wave of AI, we’re building the full value chain that makes it possible,” said Tareq Amin, CEO of HUMAIN. “Luma AI is an exceptional U.S.-based global frontier startup pushing the boundaries of multimodal world models. Their technical ambition, research velocity, and proven ability to turn foundational breakthroughs into real products make them uniquely aligned with HUMAIN’s vision. Our investment in Luma AI, combined with HUMAIN’s 2GW supercluster, positions us to train, deploy, and scale multimodal intelligence at a frontier level. This partnership sets a new benchmark for how capital, compute, and capability come together.”

The new 2-gigawatt supercluster represents a giant leap for multimodal AI infrastructure. Luma is developing technology capable of efficiently training on peta-scale multimodal data – 1,000-10,000 times more information than the current frontier Large Language Models (LLMs) to make AI useful for real-world tasks.  This cluster will also feature next-generation inference systems engineered to serve these models globally in real-time. “It is only through this level of systems and algorithmic integration that it is possible to build models that can understand and simulate the universe,” added Jain.

Ray3 , Luma AI’s flagship model, has already demonstrated Luma AI’s ability to transform foundational research into scalable commercial products, deployed widely in studios, ad agencies, and brands, including being embedded within Adobe’s global products and solutions. With this new round of funding, Luma AI plans to extend its leadership in entertainment and advertising into simulation, design, and robotics.

 As previously reported, Luma AI was the first set of models to be launched within HUMAIN Create, a regional initiative focused on building sovereign AI models and end-to-end products designed for the Arabic world. These models will understand cultural context, visual nuance, and linguistic diversity, empowering creators, enterprises, and governments to adopt AI that reflects their identity, values, and sovereignty.

About Luma AI
Luma AI is building a multimodal general intelligence that can generate, understand, and operate in the physical world. Its flagship platform, Dream Machine, enables creatives everywhere to generate professional-grade video and images. In 2025, Luma released Ray3, the world’s first reasoning video model capable of creating physically accurate videos, animations, and visuals. Luma’s models are utilized by top entertainment studios, ad agencies, and technology leaders, including Adobe and AWS, and are available via subscription or API. The company is backed by HUMAIN, Andreessen Horowitz, Amazon, AMD Ventures, NVIDIA, Amplify Partners, Matrix Partners, and angels from across the technology and entertainment space.

About HUMAIN  

HUMAIN, a PIF company, is a global artificial intelligence company delivering full-stack AI capabilities across four core areas: next-generation data centers, hyper-performance infrastructure & cloud platforms, advanced AI Models, including the world’s most advanced Arabic LLMs built in the Arab world, and transformative AI Solutions that combine deep sector insight with real-world execution.   

HUMAIN’s end-to-end model serves both public and private sector organizations, unlocking exponential value across all industries, driving transformation and strengthening capabilities through human-AI synergies. With a growing portfolio of sector-specific AI products and a core mission to drive IP leadership and talent supremacy world-wide, HUMAIN is engineered for global competitiveness and national distinction.   

www.humain.com  

Forward-Looking Statement  

This press release contains forward-looking statements based on current expectations and assumptions. Actual results may differ materially due to uncertainties. HUMAIN undertakes no obligation to update these statements. 

Media Contacts:
Peter Binazeski
Head of Communications
Luma AI
[email protected]

Hana Nemec
Head of Communications & PR
HUMAIN
[email protected]

SOURCE HUMAIN; Luma AI

Backed by Andreessen Horowitz, General Catalyst, and Blackstone, Method is developing a full-spectrum platform that enables the U.S. Government and critical enterprises to continuously test, strengthen, and evolve their defenses.

NEW YORK, Nov. 19, 2025 — Cybersecurity company Method Security today announced $26 million in combined Seed and Series A funding to accelerate the deployment of its autonomous cyber platform with the U.S. Government and critical enterprises.

The funding rounds were led by Andreessen Horowitz and General Catalyst, with participation from Blackstone Innovations Investments, Crossbeam Ventures (Michael Ovitz), NFDG, Forward Deployed Ventures, Pax Ventures, Phil Venables (Strategic Security Advisor, Google), WndrCo, Frederic Kerrest (co-founder of Okta, 515 Ventures), Ryan Noon (Chairman, Material Security), and Aaron Levie (CEO, Box).

“America’s critical institutions have been thrown into perpetual cyber conflict without the tools they need to win, while AI is enabling our adversaries to operate at unprecedented scale,” said co-founder and CEO Sam Jones. “At Method, we build systems that safely harness autonomy to deliver a decisive advantage to the teams defending what matters most.”

Method fuses offensive and defensive capabilities into a full-spectrum platform, enabling operators to achieve visibility, challenge their estates, and outpace their adversaries. By integrating diverse data sources into a digital twin, Method provides operators with an interconnected map of resources, configurations, and exposures. This serves as the foundation for simulating autonomous attacks with extreme precision and trust.

“Cyber resilience requires a system that applies autonomy for both offense and defense. We believe Method is building the team and platform our critical institutions need to defend themselves in this new paradigm,” said Mark Crane, Partner at General Catalyst.

Central to the company’s mission of defending America’s critical institutions, Method was founded as a dual-use company. The platform is deployed with customers in the Department of Defense, U.S. Federal Government, and Fortune 500.

“Cyber conflict is moving at machine speed,” said David Ulevitch, General Partner at Andreessen Horowitz. “With state actors now weaponizing AI at scale, U.S. cyber operators need new autonomous systems to compete. Method is building the first system that truly operationalizes autonomy for cyber defense: a platform that can continuously test, adapt, and strengthen our most critical institutions. Their team and technology are built to deliver that advantage.”

The company was founded by CEO Sam Jones, CTO Sean Hacker, and President Daniel Kelly. The founding team combines deep technical and operational expertise from Palantir, NSA, U.S. Air Force, CIA, AWS, CrowdStrike, Shield AI, and Microsoft.

About Method Security

Method Security builds autonomous cyber systems for America’s top security teams. Its platform fuses offensive and defensive capabilities into a trusted autonomy framework that enables continuous visibility, testing, and resilience at scale. Founded in 2023 and headquartered in New York City and Washington, D.C., Method serves the U.S. Government, Department of Defense, and Fortune 500.

SOURCE Method Security

Series C Round Led by Menlo Ventures with Participation from NVentures, Hallwood Media, Lightspeed, and Matrix

CAMBRIDGE, Mass., Nov. 19, 2025 — Suno, a music company built to amplify imagination powered by the world’s most advanced AI model, closes a $250M Series C round at a 2.45B post-money valuation, led by Menlo Ventures with participation from NVentures (NVIDIA’s venture capital arm), Hallwood Media, Lightspeed and Matrix.

“We’re seeing the future of music take shape in real time,” said Mikey Shulman, Co-Founder and CEO of Suno. “In just two years, we’ve seen millions of people make their ideas a reality through Suno, from first-time creators to top songwriters and producers integrating the tool into their daily workflows. This funding allows us to keep expanding what’s possible, empowering more artists to experiment, collaborate, and build on their creativity. We’re proud to be at the forefront of this historic moment for music.”

“Suno is the world’s #1 music creation app, making music accessible to everyone. Mikey and the team have built something people genuinely love using and millions of fans are on the platform every day, creating original songs and sharing them with friends,” said Amy Martin, Partner, Menlo Ventures.

In the past year, Suno has redefined what’s possible in music creation. In September, they launched the first-ever generative audio workstation, Suno Studio which blends pro-grade multi-track editing with AI stem generation. Days before Studio’s debut, Suno introduced v5, the company’s most powerful music model to date, delivering greater creative control, studio-quality mixing, improved vocals, and intuitive prompts across every element of a track. As part of the build-up to Suno Studio, Suno acquired WavTool, the first browser-based DAW, bringing their technology and engineering talent to now fuel Suno’s mission to empower artists with best-in-class technology. Suno is building a full-stack music ecosystem, model, workstation, artist tools, and community, designed to foster creative work rather than a one-off generation.

Unprecedented adoption across both new and established creators has signaled a cultural shift in how music can be made and shared. This funding will enable Suno to accelerate what they’re already building: more sophisticated tools for professionals, more delightful experiences for casual creators, and new ways for people to share and connect socially through music. Most importantly, Suno is building an ecosystem where everyone actively participates, rather than passively listens, and new value flows between creatives and listeners, unlocking a more promising future for the broader music community.

About Suno:

Suno is a music company built to amplify imagination. Powered by the world’s most advanced AI music model, Suno offers an unparalleled creative platform that includes Suno Studio, a breakthrough generative audio workstation. From shower-singers to aspiring songwriters to seasoned artists, Suno empowers a global community to create, share, and discover music—unlocking the joy of musical expression for all. Learn more at Suno.com.

For more information contact:
Chelsey Northern | Elana Rose | Chloé Snyder | Cory Councill
The Untold
[email protected]

SOURCE Suno

Fragmentation wastes nearly $1 trillion annually and denies patients timely, high-quality care; Arbiter collapses $100B+ in point solutions into one intelligent care orchestration platform

NEW YORK, Nov. 19, 2025 — Arbiter today emerged from stealth with $52 million in funding and a bold mission: to end healthcare fragmentation by uniting payers, providers, and patients on an AI-powered care orchestration platform. Led by TriEdge Investments and MFO Ventures, together with leading private equity firm WindRose Health Investors and other seasoned operators, this financing values Arbiter at $400 million and underscores investor conviction that healthcare needs a connected infrastructure built for real-time collaboration.

Effective patient care depends on coordination, yet today providers, payers, and patients operate in silos. The fallout is staggering: nearly one trillion dollars in annual waste and patients waiting months or abandoning care altogether. For a patient flagged at high risk for colon cancer, this can mean the difference between early detection and a late-stage diagnosis.

Arbiter ends fragmentation by bringing together data, technology, and stakeholders to close care gaps and intelligently direct next best actions – starting with real-time site-of-care optimization. The platform connects the people and systems that shape every care decision, creating a ripple effect that streamlines coordination and ensures patients move seamlessly from detection to resolution without delay.

“Arbiter’s mission is nothing less than to rebuild the operating spine of U.S. healthcare,” said Michelle Carnahan, co-founder and CEO of Arbiter. “By aligning payers and providers around the needs of patients, we’re transforming healthcare from a fragmented set of parts into a connected system that works for everyone.”

At its core is Arbiter’s Record-Action-Alignment model – a new operating foundation for healthcare. It begins with a longitudinal patient record that integrates clinical, financial, and policy data, then uses AI to automate actions and keep stakeholders in sync as care is delivered.

The company’s first application, real-time site-of-care optimization, is delivered in partnership with a leading national payer and major provider networks. The platform matches referrals to the best-fit provider based on cost, quality, and availability, and automates authorizations, outreach and scheduling. The result is care that moves faster, and more efficiently, with fewer dropped handoffs.

Over time, Arbiter’s AI will move healthcare beyond reactive fixes toward proactive management that anticipates patient needs, and ultimately to predictive intelligence that can forecast disease onset, hospital utilization, and system-wide risk. In the process, Arbiter will reshape the healthcare system from one that responds to problems into one that prevents them.

Arbiter is built and funded by leaders overseeing over $25 billion in annual healthcare payments and millions of patient lives. Its team combines executive leadership from Cigna, UnitedHealth, Kaiser Permanente, One Medical, and VillageMD with technologists from Meta, Apple, Google, and Amazon – a coalition with the experience to understand healthcare’s pain points and the expertise to solve them.

“Healthcare fragmentation isn’t an abstract problem – it’s deeply human,” said Dr. Clive Fields, Arbiter board member and co-founder of VillageMD. “Every delay or missed connection represents a patient waiting for care that should already be underway. Arbiter is uniting the system around them, so care can move at the speed of need.”

For more information, visit: arbiter.ai

About Arbiter

Arbiter is the AI-powered system that connects healthcare. By uniting patients, providers, and payers on one intelligent care orchestration platform, Arbiter ends fragmentation and ensures patients receive the right care, in the right place, at the right time.

Media Contact: [email protected]

SOURCE Arbiter